Elsevier

Neuroscience Letters

Volume 123, Issue 2, 25 February 1991, Pages 179-182
Neuroscience Letters

Determination of basal acetylcholine release in vivo by rat brain dialysis with a U-shaped cannula: effect of SM-10888, a putative therapeutic drug for Alzheimer's disease

https://doi.org/10.1016/0304-3940(91)90925-JGet rights and content

Abstract

A U-shaped dialysis cannula was implanted into rat frontal cortex, hippocampus and striatum, and after 1 day for surgical recovery the cannula was perfused with Ringer's solution without any acetylcholinesterase (AChE) inhibitor under freely moving conditions. With a highly sensitive assay method for acetylcholine (ACh), the basal ACh content in the dialysates were detectable in those brain regions for several hours. The basal levels in the frontal cortex, hippocampus and striatum were 82±9, 72±4, 70±8 fmol20μl (mean ± S.E.M.), respectively. When SM-10888, a novel AChE inhibitor and putative therapeutic drug for Alzheimer's disease, was injected intraperitoneally, ACh in the dialysate of the cortex increased in a dose-dependent manner. Changes in the levels of hippocampal and striatal ACh release evoked by SM-10888 were similar to, but smaller than, that in the cortex. These data suggest that since the present assay method is able to determine in vivo basal ACh release in the dialysate without any AChE inhibitor, it is possible to study the effect of a novel drug such as SM-10888 in the brain regions.

Cited by (24)

  • Analysis of acetylcholine from extracellular fluid in brain by in vivo microdialysis and LC-ESI-MS/MS with the stable isotope-labeled internal standard

    2011, Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences
    Citation Excerpt :

    It is generally not used as an administered drug, due to the rapid degradation by cholinesterase, but it is useful in some ophthalmological applications. It is important to determine the concentration of ACh in the extracellular fluid of the brain, to reveal changes related to Alzheimer's and Parkinson's disease [1–6]. The concentration of ACh in the extracellular fluid is relatively reliable for the evaluation of a particular neuronal activity, and could be utilized in the research on the illness mechanisms, and development of medicines for these diseases.

  • Quantitative analysis of acetylcholine in rat brain microdialysates by liquid chromatography coupled with electrospray ionization tandem mass spectrometry

    2010, Journal of Neuroscience Methods
    Citation Excerpt :

    In the CNS, ACh plays a major role in functions of memory and learning, attention, temperature control, blood pressure and sleep regulation (Wessler et al., 1998; Boonyapisit et al., 1999; Testa et al., 1996; Sarter and Bruno, 1998; Ikawa et al., 1980). Deficits in central cholinergic system are a well-known characteristic of poor cognitive performance associated with Alzheimer's disease, schizophrenia and Parkinson's disease (Davies et al., 1977; Coyle et al., 1983; Beatty et al., 1986; Xu et al., 1991; White and Cummings, 1996; Felician and Sandson, 1999). In order to provide valuable information for understanding involvement of central cholinergic transmission in disease pathology/etiology it is important to detect and monitor levels of ACh in brain extracellular fluid.

  • Chapter 3.1 Liquid chromatographic methods used for microdialysis: an overview

    2006, Handbook of Behavioral Neuroscience
    Citation Excerpt :

    This problem can partially be overcome by using an internal standard such as butyrylcholine (Kehr et al., 1998). Using the Pt-electrode, LOD's of 2 nM at best (Xu et al., 1991: Greaney et al., 1993; Carter and Kehr, 1997) have been achieved. In most cases, this sensitivity was not sufficient to be able to detect baseline release of Ach from microdialysates, so that an acetylcholine esterase inhibitor such as neostigmine or physostigmine needed to be added to the perfusion fluid for adequate quantification.

View all citing articles on Scopus
View full text